title: Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.
abstract: OBJECTIVE
  To compare the efficacy of sirolimus- and everolimus-eluting stents in patients with bifurcation lesions treated with provisional side-branch stenting.
  
  
  BACKGROUND
  The efficacy of everolimus-eluting stents in bifurcation lesions has been poorly tested.
  
  
  METHODS
  Patients with all types of Medina bifurcation lesions were randomly assigned to treatment with either a sirolimus- (n = 145) or everolimus-eluting stent (n = 148). We included patients with main vessel diameter over 2.5 mm and side branches over 2.25 mm. Patients with diffuse side-branch stenosis were excluded.
  
  
  RESULTS
  There were no significant differences between patients from the sirolimus and everolimus groups in terms of age, risk factors, clinical status, location of the bifurcation lesions or angiographic variables. Immediate results and in-hospital outcome were also similar in both groups of patients. In-hospital death occurred in two patients, one from each group. Target lesion revascularization was required in nine patients: four patients (2.7%) from the sirolimus group and five patients (3.4%) from the everolimus group. Late cardiac mortality occurred in two patients from the sirolimus group and in one patient from the everolimus group. Major cardiac event rates at 1 year were similar in both groups: nine patients (6.2%) in the sirolimus group and nine patients (6.1%) from the everolimus group (p: ns).
  
  
  CONCLUSIONS
  In patients with bifurcation lesions, no significant differences in clinical outcome at 1-year follow-up were observed between sirolimus- and everolimus-eluting stent groups.
authors.affiliation: Reina Sofia Hospital, Department of Cardiology, University of Córdoba, Avenida Melendez Pidal 1. 14001 Cordoba, Spain. manuelpan@telefonica.net
authors.forename: Manuel
authors.initials: M
authors.lastname: Pan
authors.forename: Alfonso
authors.initials: A
authors.lastname: Medina
authors.forename: Jose
authors.initials: J
authors.lastname: Suárez de Lezo
authors.forename: Miguel
authors.initials: M
authors.lastname: Romero
authors.forename: Jose
authors.initials: J
authors.lastname: Segura
authors.forename: Pedro
authors.initials: P
authors.lastname: Martín
authors.forename: Javier
authors.initials: J
authors.lastname: Suárez de Lezo
authors.forename: Enrique
authors.initials: E
authors.lastname: Hernandez
authors.forename: Francisco
authors.initials: F
authors.lastname: Mazuelos
authors.forename: Soledad
authors.initials: S
authors.lastname: Ojeda
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods* / Q000401:mortality; D011446:Prospective Studies; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus